Physician profile
John C Witherell
NPI 1811984206
$3,041.64
in general payments reported to CMS, 2019-2025
22 companies · $701 in 2025
The $701 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $182 · 2021: $391 · 2022: $550 · 2023: $413 · 2024: $649 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,762.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $587.43 | 2019-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $581.22 | 2020-2025 | Acthar |
| Horizon Therapeutics Plc | $316.78 | 2021-2023 | Tepezza |
| Alcon Vision LLC | $231.45 | 2019-2025 | Clareon, Eysuvis, Simbrinza |
| Oyster Point Pharma, INC. | $174.49 | 2022-2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $138.42 | 2024-2025 | Vevye, Iheezo |
| Amgen INC. | $132.14 | 2024-2025 | Tepezza |
| Abbvie INC. | $127.10 | 2022-2024 | Durysta |
| Kala Pharmaceuticals, INC. | $115.04 | 2019-2021 | |
| Dompe US, INC. | $111.63 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $87.20 | 2019-2021 | |
| Biotissue Holdings INC. | $83.89 | 2020-2024 | |
| Bausch & Lomb Americas INC. | $75.47 | 2022-2024 | Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $73.65 | 2024 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $50.04 | 2020-2023 | Flarex |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $36.76 | 2021 | |
| Ani Pharmaceuticals, INC. | $22.58 | 2025 | Purified Cortrophin Gel |
| Rxsight INC | $22.34 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Genentech, INC. | $22.20 | 2023 | Vabysmo |
| Allergan, INC. | $19.00 | 2022 | |
| Ocular Therapeutix, INC. | $18.10 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Witherell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.